Risk/NN
Prediction/NN
Using/VBG
Genome-Wide/NN
Association/NN
Studies/NNS
on/IN
Type/NN
2/CD
Diabetes/NNS
./.
====================
The/DT
success/NN
of/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
has/VBZ
enabled/VBN
us/PRP
to/TO
improve/VB
risk/NN
assessment/NN
and/CC
provide/VBP
novel/JJ
genetic/JJ
variants/NNS
for/IN
diagnosis/NN
,/,
prevention/NN
,/,
and/CC
treatment/NN
./.
====================
However/RB
,/,
most/JJS
variants/NNS
discovered/VBN
by/IN
GWASs/NNS
have/VBP
been/VBN
reported/VBN
to/TO
have/VB
very/RB
small/JJ
effect/NN
sizes/NNS
on/IN
complex/NN
human/JJ
diseases/NNS
,/,
which/WDT
has/VBZ
been/VBN
a/DT
big/NN
hurdle/JJ
in/IN
building/VBG
risk/NN
prediction/NN
models/NNS
./.
====================
Recently/RB
,/,
many/JJ
statistical/JJ
approaches/NNS
based/VBN
on/IN
penalized/VBN
regression/NN
have/VBP
been/VBN
developed/VBN
to/TO
solve/VB
the/DT
“/NN
large/JJ
p/NN
and/CC
small/JJ
n/NN
”/CD
problem/NN
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
evaluated/VBD
the/DT
performance/NN
of/IN
several/JJ
statistical/JJ
methods/NNS
for/IN
predicting/VBG
a/DT
binary/JJ
trait/VBP
:/:
stepwise/JJ
logistic/JJ
regression/NN
(/(
SLR/NN
)/)
,/,
least/JJS
absolute/JJ
shrinkage/NN
and/CC
selection/NN
operator/NN
(/(
LASSO/NN
)/)
,/,
and/CC
Elastic-Net/NN
(/(
EN/NN
)/)
./.
====================
We/PRP
first/RB
built/NN
a/DT
prediction/NN
model/NN
by/IN
combining/VBG
variable/JJ
selection/NN
and/CC
prediction/NN
methods/NNS
for/IN
type/NN
2/CD
diabetes/NNS
using/VBG
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
from/IN
the/DT
Korean/JJ
Association/NN
Resource/NN
project/VB
./.
====================
We/PRP
assessed/VBD
the/DT
risk/NN
prediction/NN
performance/NN
using/VBG
area/NN
under/IN
the/DT
receiver/NN
operating/VBG
characteristic/JJ
curve/JJ
(/(
AUC/NN
)/)
for/IN
the/DT
internal/JJ
and/CC
external/JJ
validation/NN
datasets/NNS
./.
====================
In/IN
the/DT
internal/JJ
validation/NN
,/,
SLR-LASSO/NN
and/CC
SLR-EN/NN
tended/VBD
to/TO
yield/VB
more/RBR
accurate/JJ
predictions/NNS
than/IN
other/JJ
combinations/NNS
./.
====================
During/IN
the/DT
external/JJ
validation/NN
,/,
the/DT
SLR-SLR/NN
and/CC
SLR-EN/NN
combinations/NNS
achieved/VBD
the/DT
highest/JJS
AUC/NN
of/IN
0.726/CD
./.
====================
We/PRP
propose/VBP
these/DT
combinations/NNS
as/IN
a/DT
potentially/RB
powerful/JJ
risk/NN
prediction/NN
model/NN
for/IN
type/NN
2/CD
diabetes/NNS
./.
====================
Genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
have/VBP
successfully/RB
identified/VBN
susceptibility/NN
variants/NNS
associated/VBN
with/IN
human/JJ
diseases/NNS
./.
====================
However/RB
,/,
most/JJS
susceptibility/NN
variants/NNS
have/VBP
small/JJ
effect/NN
sizes/NNS
and/CC
explain/VBP
only/RB
a/DT
small/JJ
proportion/NN
of/IN
heritability/NN
[/(
1/CD
]/)
./.
====================
The/DT
presence/NN
of/IN
a/DT
large/JJ
number/NN
of/IN
variants/NNS
genotyped/VBD
for/IN
a/DT
small/JJ
number/NN
of/IN
subjects/NNS
(/(
commonly/RB
known/VBN
as/IN
“/RB
large/JJ
p/NN
small/JJ
n/NN
”/CD
)/)
has/VBZ
been/VBN
one/CD
major/JJ
challenge/NN
in/IN
building/VBG
disease/NN
risk/NN
prediction/NN
models/NNS
./.
====================
Furthermore/RB
,/,
the/DT
issue/NN
of/IN
multicollinearity/JJ
arises/VBZ
when/WRB
there/EX
is/VBZ
high/JJ
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
among/IN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
./.
====================
Multiple/JJ
regression/NN
is/VBZ
very/RB
unstable/JJ
and/CC
sensitive/JJ
due/JJ
to/TO
multicollinearity/JJ
,/,
in/IN
which/WDT
the/DT
coefficient/JJ
estimates/NNS
have/VBP
very/RB
large/JJ
variances/VBZ
[/(
2/CD
]/)
./.
====================
Recently/RB
,/,
various/JJ
statistical/JJ
approaches/NNS
have/VBP
been/VBN
proposed/VBN
to/TO
cope/VB
with/IN
these/DT
issues/NNS
./.
====================
Traditional/JJ
approaches/NNS
for/IN
disease/NN
risk/NN
prediction/NN
have/VBP
been/VBN
based/VBN
on/IN
gene/NN
scores/VBZ
(/(
GSs/NNS
)/)
[/(
3456/CD
]/)
./.
====================
The/DT
marginal/JJ
effects/NNS
of/IN
previously/RB
known/VBN
disease-associated/JJ
loci/NNS
are/VBP
estimated/VBN
,/,
and/CC
then/RB
,/,
their/PRP$
sum/NN
can/MD
be/VB
used/VBN
to/TO
construct/VB
a/DT
risk/NN
prediction/NN
model/NN
./.
====================
While/IN
GS-based/JJ
approaches/NNS
can/MD
be/VB
useful/JJ
when/WRB
a/DT
genetic/JJ
variant/JJ
is/VBZ
responsible/JJ
for/IN
diseases/NNS
[/(
7/CD
]/)
,/,
they/PRP
show/VBP
low/JJ
prediction/NN
performance/NN
when/WRB
multiple/JJ
genetic/JJ
variants/NNS
exist/VBP
for/IN
a/DT
complex/JJ
disease/NN
[/(
89/CD
]/)
./.
====================
For/IN
example/NN
,/,
the/DT
prediction/NN
performance/NN
for/IN
coronary/JJ
heart/NN
and/CC
disease/NN
type/NN
2/CD
diabetes/NNS
(/(
T2D/NN
)/)
is/VBZ
only/RB
0.59/CD
and/CC
0.58/CD
,/,
respectively/RB
,/,
for/IN
area/NN
under/IN
the/DT
receiver/NN
operating/VBG
characteristic/JJ
curve/JJ
(/(
AUC/NN
)/)
values/NNS
[/(
89/CD
]/)
./.
====================
For/IN
complex/NN
diseases/NNS
,/,
a/DT
more/RBR
accurate/JJ
and/CC
reliable/JJ
prediction/NN
model/NN
is/VBZ
required/VBN
./.
====================
Multiple/JJ
logistic/JJ
regression/NN
(/(
MLR/NN
)/)
is/VBZ
a/DT
classification/NN
method/NN
that/DT
utilizes/VBZ
combined/JJ
information/NN
across/IN
multiple/JJ
genetic/JJ
variants/NNS
./.
====================
Several/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
the/DT
MLR-based/JJ
approach/NN
is/VBZ
useful/JJ
in/IN
building/VBG
a/DT
disease/NN
risk/NN
prediction/NN
model/NN
[/(
10111213/CD
]/)
./.
====================
However/RB
,/,
if/IN
there/EX
is/VBZ
large/JJ
LD/NN
between/IN
SNPs/NNS
,/,
the/DT
parameter/NN
estimates/NNS
of/IN
MLR/NN
become/VBP
unstable/JJ
,/,
and/CC
as/IN
a/DT
result/NN
,/,
the/DT
risk/NN
prediction/NN
model/NN
has/VBZ
weak/JJ
predictive/JJ
power/JJR
./.
====================
As/IN
an/DT
alternative/JJ
to/TO
MLR/NN
,/,
data/NNS
mining/VBG
approaches/NNS
have/VBP
been/VBN
used/VBN
widely/RB
to/TO
improve/VB
risk/NN
prediction/NN
performance/NN
./.
====================
In/IN
particular/JJ
,/,
support/VBP
vector/NN
machine/NN
(/(
SVM/NN
)/)
[/(
1415/CD
]/)
and/CC
random/JJ
forest/JJS
[/(
1617/CD
]/)
have/VBP
been/VBN
shown/VBN
to/TO
outperform/VB
other/JJ
classification/NN
algorithms/NNS
[/(
18/CD
]/)
./.
====================
Although/IN
these/DT
data/NNS
mining/VBG
approaches/NNS
may/MD
provide/VB
very/RB
useful/JJ
tools/NNS
in/IN
classification/NN
,/,
the/DT
effects/NNS
of/IN
genetic/JJ
variants/NNS
on/IN
a/DT
disease/NN
in/IN
prediction/NN
models/NNS
are/VBP
not/RB
easy/RB
to/TO
interpret/VB
./.
====================
Furthermore/RB
,/,
these/DT
approaches/NNS
do/VBP
not/RB
give/VB
class/NN
conditional/JJ
probabilities/NNS
of/IN
individual/JJ
predictions/NNS
[/(
19/CD
]/)
./.
====================
Thus/RB
,/,
we/PRP
focus/VBP
mainly/RB
on/IN
penalized/VBN
regression/NN
approaches/NNS
in/IN
this/DT
paper/NN
,/,
which/WDT
provides/VBZ
an/DT
individual/JJ
prediction/NN
result/NN
in/IN
terms/NNS
of/IN
probability/NN
./.
====================
As/IN
mentioned/VBN
before/IN
,/,
the/DT
problem/NN
of/IN
“/NN
large/JJ
p/NN
small/JJ
n/NN
”/CD
interrupts/NNS
the/DT
estimation/NN
of/IN
the/DT
joint/NN
effect/NN
of/IN
multiple/JJ
genetic/JJ
variants/NNS
./.
====================
In/IN
order/NN
to/TO
overcome/VB
this/DT
,/,
various/JJ
penalized/VBN
regression/NN
approaches/NNS
have/VBP
been/VBN
proposed/VBN
,/,
such/JJ
as/IN
ridge/NN
[/(
202122/CD
]/)
,/,
least/JJS
absolute/JJ
shrinkage/NN
and/CC
selection/NN
operator/NN
(/(
LASSO/NN
)/)
[/(
23/CD
]/)
,/,
and/CC
Elastic-Net/NN
(/(
EN/NN
)/)
[/(
24/CD
]/)
./.
====================
These/DT
penalized/VBD
approaches/NNS
have/VBP
an/DT
advantage/NN
in/IN
terms/NNS
of/IN
both/DT
variable/JJ
selection/NN
and/CC
prediction/NN
power/JJR
over/IN
non-penalized/JJ
approaches/NNS
for/IN
high-dimensional/JJ
data/NNS
./.
====================
For/IN
instance/NN
,/,
the/DT
prediction/NN
performance/NN
for/IN
Crohn/NN
disease/NN
and/CC
inflammatory/JJ
bowel/NN
disease/NN
using/VBG
a/DT
number/NN
of/IN
genetic/JJ
variants/NNS
with/IN
penalized/VBN
approaches/NNS
has/VBZ
been/VBN
shown/VBN
to/TO
improve/VB
[/(
2526/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
investigated/VBD
the/DT
effect/NN
of/IN
variable/JJ
selection/NN
on/IN
the/DT
performance/NN
of/IN
prediction/NN
methods/NNS
./.
====================
Especially/RB
,/,
we/PRP
considered/VBD
the/DT
following/VBG
methods/NNS
for/IN
variable/JJ
selection/NN
and/CC
prediction/NN
:/:
stepwise/JJ
logistic/JJ
regression/NN
(/(
SLR/NN
)/)
,/,
LASSO/NN
,/,
and/CC
EN/NN
./.
====================
We/PRP
compared/VBD
the/DT
effect/NN
of/IN
variable/JJ
selection/NN
on/IN
the/DT
performance/NN
of/IN
prediction/NN
by/IN
applying/VBG
them/PRP
to/TO
T2D/NN
GWAS/NN
chip/NN
data/NNS
./.
====================
We/PRP
constructed/VBD
the/DT
prediction/NN
models/NNS
by/IN
combining/VBG
variable/JJ
selection/NN
and/CC
prediction/NN
methods/NNS
using/VBG
the/DT
Korean/JJ
Association/NN
Resource/NN
(/(
KARE/NN
)/)
GWAS/NN
dataset/NN
(/(
3,180/CD
individuals/NNS
)/)
and/CC
then/RB
evaluated/VBD
the/DT
performance/NN
of/IN
the/DT
risk/NN
prediction/NN
model/NN
through/IN
both/DT
internal/JJ
validation/NN
(/(
805/CD
individuals/NNS
in/IN
the/DT
KARE/NN
testing/VBG
dataset/NN
)/)
and/CC
external/JJ
validation/NN
(/(
4,723/CD
individuals/NNS
in/IN
an/DT
external/JJ
replication/NN
dataset/RB
)/)
./.
====================
The/DT
external/JJ
replication/NN
dataset/NN
combined/JJ
two/CD
cohorts/NNS
:/:
the/DT
Health2/NN
study/NN
(/(
1,816/CD
individuals/NNS
)/)
and/CC
Health/NN
Examinee/NN
(/(
HEXA/NN
)/)
study/NN
(/(
3,696/CD
individuals/NNS
)/)
./.
====================
In/IN
both/DT
the/DT
internal/JJ
and/CC
external/JJ
validation/NN
datasets/NNS
,/,
we/PRP
measured/VBD
the/DT
discriminative/JJ
accuracy/NN
of/IN
the/DT
prediction/NN
models/NNS
using/VBG
AUC/NN
./.
====================
KARE/NN
dataset/NN
====================
The/DT
KARE/NN
project/VB
was/VBD
initiated/VBN
in/IN
2007/CD
to/TO
undertake/VB
a/DT
large-scale/JJ
GWAS/NN
with/IN
10,038/CD
participants/NNS
from/IN
two/CD
community-based/VBN
cohorts/NNS
(/(
i.e./FW
,/,
the/DT
rural/JJ
Anseong/JJ
and/CC
urban/JJ
Ansan/NN
cohorts/NNS
)/)
./.
====================
Among/IN
the/DT
participants/NNS
,/,
10,004/CD
samples/NNS
were/VBD
genotyped/VBN
using/VBG
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
From/IN
sample/NN
and/CC
SNP/NN
quality/NN
controls/NNS
,/,
a/DT
total/JJ
of/IN
8,842/CD
individuals/NNS
were/VBD
selected/VBN
from/IN
the/DT
Anseong/JJ
(/(
2,374/CD
men/NNS
and/CC
2,263/CD
women/NNS
)/)
and/CC
Ansan/NN
(/(
1,809/CD
men/NNS
and/CC
2,396/CD
women/NNS
)/)
cohorts/VBZ
[/(
27/CD
]/)
./.
====================
Missing/VBG
genotypes/NNS
were/VBD
imputed/VBN
using/VBG
the/DT
Beale/JJ
software/JJ
program/NN
[/(
28/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
a/DT
total/JJ
of/IN
3,985/CD
samples/NNS
were/VBD
selected/VBN
from/IN
among/IN
the/DT
8,842/CD
individuals/NNS
using/VBG
T2D/NN
diagnostic/JJ
criteria/NNS
[/(
2930/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
1,042/CD
subjects/NNS
were/VBD
included/VBN
in/IN
the/DT
T2D/NN
group/NN
according/VBG
to/TO
the/DT
following/VBG
criteria/NNS
:/:
(/(
1/LS
)/)
fasting/VBG
plasma/NN
glucose/NN
(/(
FPG/NN
)/)
larger/RBR
than/IN
or/CC
equal/JJ
to/TO
126/CD
mg/dL/NN
,/,
2-hour/JJ
postprandial/JJ
blood/NN
glucose/NN
(/(
Glu120/NN
)/)
larger/RBR
than/IN
or/CC
equal/JJ
to/TO
200/CD
mg/dL/NN
,/,
(/(
2/CD
)/)
treatment/NN
of/IN
T2D/NN
,/,
and/CC
(/(
3/LS
)/)
age/NN
of/IN
disease/NN
onset/NN
≥/NNP
40/CD
years/NNS
./.
====================
The/DT
inclusion/NN
criteria/NNS
for/IN
nondiabetic/JJ
normal/JJ
subjects/NNS
(/(
n/NN
=/JJ
2,943/CD
)/)
were/VBD
as/IN
follows/VBZ
:/:
(/(
1/CD
)/)
FPG/NN
less/RBR
than/IN
or/CC
equal/JJ
to/TO
100/CD
mg/dL/NN
or/CC
Glu120/NN
less/RBR
than/IN
or/CC
equal/JJ
to/TO
140/CD
mg/dL/NN
and/CC
(/(
2/CD
)/)
no/DT
history/JJ
of/IN
diabetes/NNS
./.
====================
The/DT
demographic/JJ
variables/NNS
of/IN
the/DT
subjects/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
Health2/NN
and/CC
HEXA/NN
datasets/NNS
====================
We/PRP
combined/VBD
two/CD
Korean/JJ
GWASs/NNS
,/,
the/DT
Health2/NN
study/NN
(/(
n/NN
=/JJ
1,816/CD
)/)
and/CC
the/DT
HEXA/NN
study/NN
(/(
n/NN
=/JJ
3,696/CD
)/)
./.
====================
The/DT
Health2/NN
study/NN
consists/VBZ
of/IN
community-based/VBN
cohorts/NNS
from/IN
5/CD
rural/JJ
areas/NNS
(/(
i.e./FW
,/,
Wonju/NNP
,/,
Pyeongchang/NNP
,/,
Gangneung/JJ
,/,
Geumsan/NNP
,/,
and/CC
Naju/NN
)/)
,/,
and/CC
the/DT
HEXA/NN
study/NN
is/VBZ
a/DT
cohort/JJ
from/IN
14/CD
urban/JJ
areas/NNS
./.
====================
These/DT
samples/NNS
were/VBD
genotyped/VBN
using/VBG
the/DT
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
array/NN
6.0/CD
./.
====================
The/DT
Health2/NN
and/CC
the/DT
HEXA/NN
cohorts/NNS
have/VBP
been/VBN
described/VBN
in/IN
previous/JJ
studies/NNS
[/(
273132/CD
]/)
./.
====================
Missing/VBG
genotypes/NNS
were/VBD
were/VBD
imputed/VBN
using/VBG
Beagle/JJ
software/JJ
./.
====================
Our/PRP$
investigation/NN
was/VBD
based/VBN
on/IN
the/DT
analysis/NN
of/IN
an/DT
external/JJ
replication/NN
dataset/NN
of/IN
4,723/CD
samples/NNS
(/(
1,112/CD
T2D/NN
subjects/NNS
,/,
3,611/CD
normal/JJ
subjects/NNS
)/)
for/IN
T2D/NN
[/(
33/CD
]/)
./.
====================
The/DT
criteria/NNS
for/IN
grouping/VBG
T2D/NN
subjects/NNS
(/(
nHealth2/NN
=/JJ
794/CD
,/,
nHEXA/RB
=/JJ
318/CD
)/)
and/CC
nondiabetic/JJ
normal/JJ
subjects/NNS
(/(
nHealth2/NN
=/JJ
770/CD
,/,
nHEXA/RB
=/JJ
2,841/CD
)/)
were/VBD
FPG/NN
level/NN
(/(
FPG/NN
≥/CD
126/CD
for/IN
T2D/NN
subjects/NNS
and/CC
FPG/NN
≤/CD
100/CD
for/IN
nondiabetic/JJ
normal/JJ
subjects/NNS
)/)
and/CC
history/JJ
of/IN
T2D/NN
treatment/NN
./.
====================
The/DT
demographic/JJ
variables/NNS
of/IN
the/DT
subjects/NNS
in/IN
the/DT
Health2/NN
and/CC
HEXA/NN
cohorts/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
Statistical/JJ
analysis/NN
====================
For/IN
the/DT
joint/NN
identification/NN
of/IN
disease/NN
susceptibility/NN
variants/NNS
among/IN
a/DT
large/JJ
number/NN
of/IN
SNPs/NNS
,/,
we/PRP
extracted/VBD
SNPs/NNS
having/VBG
a/DT
strong/JJ
correlation/NN
with/IN
T2D/NN
via/IN
logistic/JJ
regression/NN
for/IN
single-variant/JJ
analysis/NN
and/CC
collected/JJ
the/DT
list/NN
of/IN
reported/VBN
SNPs/NNS
from/IN
a/DT
GWAS/JJ
catalog/NN
[/(
34/CD
]/)
./.
====================
Then/RB
,/,
we/PRP
implemented/VBD
a/DT
3-stage/JJ
procedure/NN
as/IN
follows/VBZ
:/:
the/DT
first/JJ
stage/NN
was/VBD
variable/JJ
selection/NN
using/VBG
SLR/NN
,/,
LASSO/NN
,/,
and/CC
EN/NN
./.
====================
The/DT
second/JJ
stage/NN
was/VBD
the/DT
construction/NN
of/IN
risk/NN
prediction/NN
models/NNS
./.
====================
The/DT
third/JJ
stage/NN
was/VBD
evaluation/NN
of/IN
the/DT
risk/NN
prediction/NN
models/NNS
through/IN
both/CC
internal/JJ
validation/NN
and/CC
external/JJ
validation/NN
./.
====================
SNP/NN
sets/NNS
====================
Because/IN
the/DT
components/NNS
of/IN
SNPs/NNS
seem/VBP
to/TO
be/VB
related/JJ
to/TO
the/DT
performance/NN
of/IN
risk/NN
prediction/NN
,/,
we/PRP
used/VBD
two/CD
data/NNS
sources/NNS
(/(
i.e./FW
,/,
the/DT
GWAS/NN
catalog/NN
and/CC
KARE/NN
cohort/NN
)/)
./.
====================
First/RB
,/,
we/PRP
collected/VBD
the/DT
SNPs/NNS
,/,
p1/NN
,/,
from/IN
a/DT
GWAS/JJ
catalog/NN
in/IN
all/DT
populations/NNS
and/CC
an/DT
Asian/JJ
population/NN
only/RB
./.
====================
Second/RB
,/,
the/DT
SNPs/NNS
were/VBD
selected/VBN
by/IN
single-variant/JJ
association/NN
test/NN
using/VBG
logistic/JJ
regression/NN
,/,
with/IN
adjustments/NNS
for/IN
age/NN
,/,
sex/NN
,/,
area/NN
(/(
namely/RB
,/,
rural/JJ
area/NN
of/IN
Anseong/JJ
and/CC
urban/JJ
area/NN
of/IN
Ansan/JJ
)/)
,/,
and/CC
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
./.
====================
We/PRP
chose/VBP
the/DT
top-ranked/JJ
p2/NN
SNPs/NNS
by/IN
the/DT
order/NN
of/IN
p-values/NNS
from/IN
the/DT
KARE/NN
cohort/NN
./.
====================
In/IN
Table/JJ
2/CD
,/,
we/PRP
have/VBP
categorized/VBN
five/CD
SNP/NN
sets/NNS
./.
====================
(/(
1/CD
)/)
ALL/NN
(/(
SNPs/NNS
only/RB
reported/VBD
in/IN
the/DT
GWAS/NN
catalog/NN
)/)
====================
(/(
2/CD
)/)
ASIAN/NN
(/(
SNPs/NNS
only/RB
reported/VBD
in/IN
the/DT
GWAS/NN
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
)/)
====================
(/(
3/CD
)/)
KARE/NN
(/(
only/RB
top-ranked/VBN
p2/NN
SNPs/NNS
in/IN
the/DT
KARE/NN
cohort/NN
)/)
====================
(/(
4/CD
)/)
ALL/NN
+/JJ
KARE/NN
(/(
combined/VBN
SNPs/NNS
in/IN
the/DT
GWAS/NN
catalog/NN
and/CC
KARE/NN
cohort/NN
)/)
====================
(/(
5/CD
)/)
ASIAN/NN
+/JJ
KARE/NN
(/(
combined/VBN
SNPs/NNS
in/IN
the/DT
GWAS/NN
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
and/CC
the/DT
KARE/NN
cohort/NN
)/)
====================
Stage/NN
1/CD
:/:
Variable/JJ
selection/NN
====================
In/IN
the/DT
KARE/NN
dataset/NN
,/,
we/PRP
separated/VBD
3,985/CD
individuals/NNS
(/(
1,042/CD
T2D/NN
subjects/NNS
,/,
2,943/CD
normal/JJ
subjects/NNS
)/)
into/IN
a/DT
training/JJ
set/NN
of/IN
3,180/CD
individuals/NNS
(/(
830/CD
T2D/NN
subjects/NNS
,/,
2,350/CD
normal/JJ
subjects/NNS
)/)
and/CC
a/DT
test/NN
set/NN
of/IN
805/CD
individuals/NNS
(/(
212/CD
T2D/NN
subjects/NNS
,/,
593/CD
normal/JJ
subjects/NNS
)/)
(/(
see/VB
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
variable/JJ
selection/NN
was/VBD
performed/VBN
using/VBG
5-fold/JJ
cross-validation/NN
(/(
CV/NN
)/)
on/IN
the/DT
training/VBG
set/NN
./.
====================
We/PRP
describe/VBP
the/DT
details/NNS
below/IN
./.
====================
The/DT
phenotype/NN
yi/IN
of/IN
subject/JJ
i/LS
=/JJ
1/CD
,/,
…/NNP
,/,
n/NN
was/VBD
set/RB
as/IN
a/DT
dependent/JJ
variable/JJ
(/(
T2D/NN
=/JJ
1/CD
,/,
normal/JJ
=/JJ
0/CD
)/)
,/,
and/CC
the/DT
genotype/JJ
xij/CC
of/IN
the/DT
j-th/JJ
SNP/NN
(/(
j/RB
=/JJ
1/CD
,/,
…/NNP
,/,
p/NN
)/)
for/IN
subject/JJ
i/LS
was/VBD
set/RB
as/IN
an/DT
independent/JJ
variable/JJ
with/IN
an/DT
additive/JJ
genetic/JJ
model/NN
(/(
AA/NNP
=/JJ
0/CD
,/,
Aa/NNP
=/JJ
1/CD
,/,
aa=2/RB
,/,
where/WRB
A/DT
and/CC
a/DT
indicate/VBP
the/DT
major/JJ
and/CC
minor/JJ
alleles/NNS
,/,
respectively/RB
)/)
./.
====================
For/IN
variable/JJ
selection/NN
,/,
the/DT
following/VBG
SLR/NN
was/VBD
conducted/VBN
./.
====================
logP/NN
(/(
yi=1/NN
)/)
1−P/NN
(/(
yi=1/NN
)/)
=β0+∑j=1pβjxij+γ1AGEi+γ2SEXi+γ3AREAi+γ4BMIi/NN
,/,
where/WRB
β0/CD
and/CC
βj/FW
are/VBP
the/DT
intercept/NN
and/CC
effect/NN
sizes/NNS
of/IN
SNPs/NNS
,/,
respectively/RB
./.
====================
γ1/RB
,/,
γ2/NN
,/,
γ3/RB
,/,
and/CC
γ4/NN
represent/JJ
the/DT
age/NN
,/,
sex/NN
,/,
area/NN
(/(
namely/RB
,/,
rural/JJ
and/CC
urban/JJ
areas/NNS
)/)
,/,
and/CC
BMI/NN
of/IN
the/DT
i-th/NN
individuals/NNS
,/,
respectively/RB
./.
====================
For/IN
the/DT
given/VBN
covariates/VBZ
,/,
the/DT
selection/NN
of/IN
SNPs/NNS
was/VBD
determined/VBN
by/IN
a/DT
stepwise/JJ
procedure/NN
based/VBN
on/IN
Akaike/JJ
’/CD
s/NNS
information/NN
criterion/NN
[/(
35/CD
]/)
./.
====================
The/DT
stepwise/JJ
procedure/NN
was/VBD
conducted/VBN
using/VBG
the/DT
R-package/NN
MASS/NN
[/(
36/CD
]/)
./.
====================
The/DT
penalized/JJ
method/NN
solves/RB
the/DT
following/VBG
:/:
minβ0/RB
,/,
β/RB
,/,
γ∑i=1n/RB
(/(
yi−β0−X′iβ−COV′iγ/RB
)/)
2+Pλ/RB
(/(
β/RB
)/)
,/,
where/IN
Xi/NNP
=/JJ
(/(
xi1/RB
,/,
…/NNP
,/,
xij/CC
,/,
…/NNP
,/,
xip/RB
)/)
T/NN
and/CC
COVi/NNP
=/JJ
(/(
AGEi/NNP
,/,
SEXi/NNP
,/,
AREAi/NNP
,/,
BMIi/NNP
)/)
T/NN
for/IN
the/DT
i-th/DT
subject/JJ
,/,
β/RB
=/JJ
(/(
β1/RB
,/,
…/NNP
,/,
βj/RB
,/,
…/NNP
,/,
βp/RB
)/)
T/NN
,/,
and/CC
γ/IN
=/JJ
(/(
γ1/RB
,/,
γ2/RB
,/,
γ3/RB
,/,
γ4/RB
)/)
T./FW
Lasso/RB
and/CC
EN/JJ
penalties/NNS
are/VBP
defined/VBN
as/IN
Pλ/JJ
(/(
β/RB
)/)
=/JJ
λΣ|β|/RB
and/CC
Pλ/NNP
(/(
β/RB
)/)
=/JJ
λ/RB
[/(
(/(
1/LS
−/RB
α/RB
)/)
Σ|β|/RB
+/CC
αΣβ2/RB
]/)
,/,
respectively/RB
./.
====================
λ/RB
and/CC
α/FW
are/VBP
a/DT
tuning/JJ
parameter/NN
and/CC
a/DT
weight/NN
of/IN
a/DT
value/NN
between/IN
0/CD
to/TO
1/CD
,/,
respectively/RB
./.
====================
All/DT
penalized/VBN
methods/NNS
were/VBD
conducted/VBN
using/VBG
the/DT
R-package/NN
glmnet/NN
[/(
37/CD
]/)
./.
====================
Then/RB
,/,
we/PRP
defined/VBD
five/CD
sets/NNS
as/IN
follows/VBZ
:/:
====================
(/(
1/CD
)/)
One/CD
set/NN
:/:
set/NN
of/IN
SNPs/NNS
that/DT
have/VBP
a/DT
non-zero/JJ
coefficient/JJ
at/IN
least/JJS
one/CD
time/NN
among/IN
the/DT
5-fold/JJ
CV/NN
====================
(/(
2/CD
)/)
Two/CD
set/NN
:/:
set/NN
of/IN
SNPs/NNS
that/DT
have/VBP
a/DT
non-zero/JJ
coefficient/JJ
at/IN
least/JJS
two/CD
times/NNS
among/IN
the/DT
5-fold/JJ
CV/NN
====================
(/(
3/CD
)/)
Three/CD
set/NN
:/:
set/NN
of/IN
SNPs/NNS
that/DT
have/VBP
a/DT
non-zero/JJ
coefficient/JJ
at/IN
least/JJS
three/CD
times/NNS
among/IN
the/DT
5-fold/JJ
CV/NN
====================
(/(
4/CD
)/)
Four/CD
set/NN
:/:
set/NN
of/IN
SNPs/NNS
that/DT
have/VBP
a/DT
non-zero/JJ
coefficient/JJ
at/IN
least/JJS
four/CD
times/NNS
among/IN
the/DT
5-fold/JJ
CV/NN
====================
(/(
5/CD
)/)
Five/CD
set/NN
:/:
set/NN
of/IN
SNPs/NNS
having/VBG
non-zero/NN
coefficients/NNS
in/IN
the/DT
5-fold/JJ
CV/NN
,/,
====================
where/WRB
one/CD
set/NN
⊃/CD
two/CD
set/NN
⊃/CD
three/CD
set/NN
⊃/CD
four/CD
set/NN
⊃/CD
five/CD
set/NN
./.
====================
Stage/NN
2/CD
:/:
Construction/NN
of/IN
risk/NN
prediction/NN
models/NNS
====================
For/IN
construction/NN
of/IN
the/DT
risk/NN
prediction/NN
model/NN
,/,
we/PRP
considered/VBD
9/CD
combinations/NNS
of/IN
variable/JJ
selection/NN
and/CC
prediction/NN
methods/NNS
(/(
i.e./FW
,/,
SLR-SLR/NN
,/,
SLR-LASSO/NN
,/,
SLR-EN/NN
,/,
LASSO-SLR/NN
,/,
LASSO-LASSO/NN
,/,
LASSO-EN/NN
,/,
EN-SLR/NN
,/,
EN-LASSO/NN
,/,
and/CC
EN-EN/NN
)/)
./.
====================
For/IN
each/DT
combination/NN
,/,
we/PRP
constructed/VBD
prediction/NN
models/NNS
using/VBG
the/DT
entire/JJ
KARE/NN
training/VBG
dataset/NN
(/(
n/NN
=/JJ
3,180/CD
)/)
./.
====================
Stage/NN
3/CD
:/:
Evaluation/NN
of/IN
risk/NN
prediction/NN
models/NNS
====================
For/IN
evaluating/VBG
the/DT
risk/NN
prediction/NN
performance/NN
,/,
we/PRP
needed/VBD
to/TO
assess/VB
both/CC
internally/RB
and/CC
externally/RB
to/TO
determine/VB
the/DT
performance/NN
of/IN
the/DT
prediction/NN
models/NNS
./.
====================
To/TO
validate/VB
the/DT
risk/NN
prediction/NN
methods/NNS
,/,
we/PRP
used/VBD
internal/JJ
and/CC
external/JJ
validation/NN
datasets/NNS
from/IN
the/DT
KARE/NN
testing/VBG
dataset/NN
(/(
n/NN
=/JJ
805/CD
)/)
and/CC
an/DT
external/JJ
replication/NN
dataset/NN
(/(
n/NN
=/JJ
4,723/CD
)/)
,/,
respectively/RB
./.
====================
In/IN
both/DT
the/DT
internal/JJ
and/CC
external/JJ
validation/NN
datasets/NNS
,/,
we/PRP
used/VBD
the/DT
AUC/NN
of/IN
the/DT
receiver/NN
operator/NN
characteristic/JJ
(/(
ROC/NN
)/)
curve/VBP
,/,
which/WDT
is/VBZ
widely/RB
used/VBN
for/IN
risk/NN
prediction/NN
performance/NN
[/(
3839/CD
]/)
./.
====================
The/DT
ROC/NN
curve/JJ
is/VBZ
a/DT
graphical/JJ
plot/NN
of/IN
sensitivity/NN
(/(
true/JJ
positive/JJ
rate/NN
)/)
against/IN
1/CD
–/NN
specificity/NN
(/(
false-positive/JJ
rate/NN
)/)
across/IN
all/DT
possible/JJ
threshold/NN
values/NNS
./.
====================
A/DT
summary/NN
measure/VB
of/IN
ROC/NN
curves/NNS
,/,
such/JJ
as/IN
AUC/NN
,/,
is/VBZ
indicated/VBN
as/IN
the/DT
discriminative/JJ
accuracy/NN
./.
====================
An/DT
AUC/NN
score/RB
close/JJ
to/TO
0.5/CD
reflects/VBZ
random/JJ
chance/NN
,/,
while/IN
AUC/NN
values/NNS
closer/NN
to/TO
1/CD
indicate/VBP
perfect/IN
accuracy/NN
./.
====================
Preparing/VBG
SNP/NN
sets/NNS
====================
The/DT
association/NN
of/IN
T2D/NN
was/VBD
analyzed/VBN
using/VBG
logistic/JJ
regression/NN
with/IN
adjustments/NNS
for/IN
age/NN
,/,
sex/NN
,/,
area/NN
,/,
and/CC
BMI/NN
as/IN
covariates/VBZ
./.
====================
As/IN
shown/VBN
in/IN
Supplementary/JJ
Fig/NN
./.
====================
1A/NN
,/,
the/DT
quantile-quantile/JJ
plot/NN
shows/VBZ
that/IN
the/DT
observed/VBN
p/NN
-values/NNS
at/IN
the/DT
tail/NN
are/VBP
significantly/RB
larger/JJR
than/IN
the/DT
null/JJ
distribution/NN
./.
====================
Six/CD
SNPs/NNS
in/IN
CDKAL1/NN
had/VBD
associations/NNS
that/IN
reached/VBD
a/DT
genome-wide/JJ
significance/NN
level/NN
of/IN
p-value/JJ
less/RBR
than/IN
1.45/CD
×/CD
10−7/CD
(/(
Supplementary/JJ
Table/JJ
1/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Supplementary/JJ
Table/JJ
1/CD
shows/VBZ
the/DT
results/NNS
with/IN
a/DT
p-value/JJ
threshold/NN
of/IN
less/RBR
than/IN
5.00/CD
×/CD
10−5/CD
./.
====================
rs7754840/CD
(/(
p/NN
=/JJ
4.66/CD
×/CD
10−8/CD
)/)
of/IN
CDKAL1/NN
and/CC
rs10811661/NN
(/(
p/NN
=/JJ
7.17/CD
×/CD
10−6/CD
)/)
of/IN
CDKN2A/2B/NN
have/VBP
been/VBN
observed/VBN
to/TO
affect/VB
T2D/NN
in/IN
previous/JJ
GWASs/NNS
[/(
404142434445/CD
]/)
./.
====================
In/IN
the/DT
GWAS/NN
catalog/NN
,/,
we/PRP
found/VBD
65/CD
SNPs/NNS
and/CC
25/CD
SNPs/NNS
associated/VBN
with/IN
T2D/NN
in/IN
all/DT
populations/NNS
and/CC
the/DT
Asian/JJ
population/NN
,/,
respectively/RB
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
As/IN
previously/RB
mentioned/JJ
,/,
we/PRP
categorized/VBD
five/CD
SNP/NN
sets/NNS
from/IN
two/CD
data/NNS
sources/NNS
in/IN
Table/JJ
2/CD
./.
====================
Selection/NN
of/IN
predictor/NN
variables/NNS
====================
In/IN
each/DT
SNP/NN
set/NN
,/,
the/DT
variable/JJ
selection/NN
methods/NNS
were/VBD
applied/VBN
to/TO
5-fold/JJ
CV/NN
on/IN
the/DT
training/VBG
set/NN
./.
====================
Fig/NN
./.
====================
2/CD
shows/VBZ
information/NN
about/IN
the/DT
number/NN
of/IN
overlapping/VBG
SNPs/NNS
by/IN
5-fold/JJ
CV/NN
for/IN
each/DT
variable/JJ
selection/NN
method/NN
./.
====================
Table/JJ
3/CD
provides/VBZ
a/DT
summary/NN
of/IN
the/DT
results/NNS
of/IN
the/DT
variable/JJ
selection/NN
./.
====================
The/DT
variable/JJ
selection/NN
methods/NNS
gave/VBD
very/RB
similar/JJ
results/NNS
in/IN
the/DT
ALL/NN
and/CC
ASIAN/NN
datasets/NNS
,/,
whereas/IN
the/DT
results/NNS
showed/VBD
differences/NNS
among/IN
the/DT
methods/NNS
in/IN
the/DT
KARE/NN
and/CC
ALL/NN
+/JJ
KARE/NN
datasets/NNS
./.
====================
Furthermore/RB
,/,
SLR/NN
generally/RB
tended/VBN
to/TO
select/VB
a/DT
smaller/JJR
number/NN
of/IN
SNPs/NNS
than/IN
LASSO/NN
and/CC
EN/NN
./.
====================
Construction/NN
of/IN
prediction/NN
models/NNS
and/CC
validation/NN
in/IN
testing/VBG
datasets/NNS
====================
We/PRP
fitted/VBD
the/DT
prediction/NN
models/NNS
using/VBG
SLR/NN
,/,
LASSO/NN
,/,
and/CC
EN/NN
using/VBG
the/DT
entire/JJ
training/VBG
individuals/NNS
in/IN
the/DT
KARE/NN
cohort/NN
./.
====================
Then/RB
,/,
we/PRP
applied/VBD
the/DT
prediction/NN
models/NNS
to/TO
the/DT
KARE/NN
testing/NN
dataset/NN
and/CC
an/DT
external/JJ
replication/NN
dataset/NN
./.
====================
The/DT
prediction/NN
models/NNS
were/VBD
built/RB
based/VBN
on/IN
Affymetrix/JJ
5.0/CD
,/,
but/CC
the/DT
external/JJ
replication/NN
dataset/NN
was/VBD
generated/VBN
by/IN
Affymetrix/JJ
6.0/CD
./.
====================
In/IN
the/DT
case/NN
of/IN
the/DT
KARE/NN
dataset/NN
,/,
nearly/RB
90/CD
%/NN
of/IN
the/DT
SNPs/NNS
belonged/VBD
to/TO
the/DT
external/JJ
replication/NN
dataset/NN
./.
====================
Thus/RB
,/,
we/PRP
did/VBD
not/RB
include/VB
untyped/JJ
SNPs/NNS
in/IN
the/DT
evaluation/NN
of/IN
prediction/NN
models/NNS
using/VBG
the/DT
replication/NN
dataset/NN
./.
====================
Among/IN
the/DT
five/CD
SNP/NN
sets/NNS
,/,
Fig/NN
./.
====================
3/CD
shows/VBZ
that/IN
the/DT
prediction/NN
models/NNS
from/IN
the/DT
KARE/NN
SNP/NN
set/NN
had/VBD
higher/JJR
AUC/NN
values/NNS
for/IN
the/DT
KARE/NN
testing/NN
dataset/NN
than/IN
other/JJ
SNP/NN
sets/NNS
./.
====================
In/IN
contrast/NN
,/,
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
4/CD
,/,
the/DT
prediction/NN
models/NNS
from/IN
ALL/NN
+/JJ
KARE/NN
had/VBD
the/DT
best/JJS
performance/NN
overall/JJ
for/IN
the/DT
external/JJ
replication/NN
dataset/NN
./.
====================
In/IN
Table/JJ
4/CD
,/,
the/DT
best/JJS
combinations/NNS
of/IN
the/DT
variable/JJ
selection/NN
and/CC
prediction/NN
models/NNS
had/VBD
the/DT
highest/JJS
AUC/NN
values/NNS
./.
====================
SLR-LASSO/NN
and/CC
SLR-EN/NN
with/IN
three/CD
set/NN
from/IN
KARE/NN
had/VBD
an/DT
AUC/NN
of/IN
0.816/CD
in/IN
the/DT
KARE/NN
testing/NN
dataset/NN
./.
====================
In/IN
an/DT
external/JJ
replication/NN
dataset/NN
,/,
SLR-SLR/NN
and/CC
SLR-EN/NN
with/IN
one/CD
set/NN
from/IN
ALL/NN
+/CC
KARE/NN
(/(
AUC/NN
,/,
0.726/CD
)/)
were/VBD
the/DT
best/JJS
,/,
with/IN
51/CD
SNPs/NNS
for/IN
T2D/NN
,/,
while/IN
SLR-LASSO/NN
and/CC
SLR-EN/NN
with/IN
three/CD
set/NN
from/IN
KARE/NN
(/(
AUC/NN
,/,
0.590/CD
)/)
showed/VBD
the/DT
best/JJS
performance/RB
,/,
with/IN
53/CD
SNPs/NNS
./.
====================
SLR-SLR/NN
with/IN
one/CD
set/NN
from/IN
ALL/NN
+/JJ
KARE/NN
was/VBD
superior/JJ
to/TO
the/DT
model/NN
with/IN
only/RB
demographic/JJ
variables/NNS
(/(
15.7/CD
%/NN
increase/VBP
in/IN
AUC/NN
)/)
./.
====================
Among/IN
the/DT
51/CD
SNPs/NNS
of/IN
SLR-SLR/NN
with/IN
one/CD
set/NN
from/IN
ALL/NN
+/JJ
KARE/NN
,/,
38/CD
SNPs/NNS
were/VBD
mapped/VBN
to/TO
the/DT
genes/NNS
(/(
Table/JJ
5/CD
)/)
./.
====================
Some/DT
genes/NNS
(/(
AGR3/NN
,/,
C2CD4B/NN
,/,
C6orf57/NN
,/,
CAMK1D/NN
,/,
DNER/NN
,/,
IGF2BP2/NN
,/,
KCNJ11/NN
,/,
KCNQ1/NN
,/,
NXN/NN
,/,
PLS1/NN
,/,
and/CC
RGS7/NN
)/)
were/VBD
previously/RB
reported/VBD
to/TO
be/VB
associated/VBN
with/IN
T2D/NN
[/(
44454647484950515253/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
compared/VBD
the/DT
performance/NN
of/IN
risk/NN
prediction/NN
models/NNS
combining/VBG
variable/JJ
selection/NN
and/CC
prediction/NN
methods/NNS
./.
====================
Also/RB
,/,
the/DT
effect/NN
of/IN
five/CD
SNP/NN
sets/NNS
(/(
i.e./FW
,/,
ALL/NN
,/,
ASIAN/NN
,/,
KARE/NN
,/,
ALL/NN
+/JJ
KARE/NN
,/,
and/CC
ASIAN/NN
+/JJ
KARE/NN
)/)
on/IN
risk/NN
prediction/NN
performance/NN
was/VBD
investigated/VBN
./.
====================
Overall/RB
,/,
we/PRP
confirmed/VBD
that/IN
prediction/NN
models/NNS
incorporating/VBG
both/CC
demographic/JJ
variables/NNS
and/CC
genetic/JJ
variables/NNS
were/VBD
more/RBR
accurate/JJ
than/IN
prediction/NN
models/NNS
using/VBG
only/RB
demographic/JJ
variables/NNS
./.
====================
According/VBG
to/TO
our/PRP$
results/NNS
,/,
the/DT
best/JJS
combinations/NNS
were/VBD
SLR-LASSO/NN
and/CC
SLR-EN/NN
with/IN
three/CD
set/NN
from/IN
the/DT
KARE/NN
SNP/NN
set/NN
in/IN
the/DT
KARE/NN
testing/VBG
dataset/NN
,/,
whereas/IN
the/DT
SLR-SLR/NN
and/CC
SLR-EN/NN
combination/NN
with/IN
one/CD
set/NN
from/IN
the/DT
ALL/NN
+/CC
KARE/NN
SNP/NN
set/NN
outperformed/VBN
all/DT
other/JJ
combinations/NNS
in/IN
an/DT
external/JJ
replication/NN
dataset/NN
./.
====================
The/DT
analysis/NN
of/IN
risk/NN
prediction/NN
studies/NNS
can/MD
be/VB
extended/VBN
in/IN
several/JJ
ways/NNS
./.
====================
First/RB
,/,
the/DT
performance/NN
of/IN
a/DT
risk/NN
prediction/NN
model/NN
can/MD
be/VB
improved/VBN
by/IN
incorporating/VBG
rare/JJ
variants/NNS
./.
====================
Advances/NNS
in/IN
sequencing/NN
technology/NN
make/VBP
it/PRP
possible/JJ
to/TO
investigate/VB
the/DT
role/NN
of/IN
common/JJ
and/CC
rare/JJ
variants/NNS
in/IN
risk/NN
prediction/NN
of/IN
complex/NN
diseases/NNS
./.
====================
Wei/NNS
and/CC
Lu/FW
[/(
54/CD
]/)
proposed/VBN
a/DT
collapsing/JJ
ROC/NN
approach/NN
that/DT
incorporates/VBZ
genetic/JJ
information/NN
from/IN
both/CC
common/JJ
and/CC
rare/JJ
variants/NNS
./.
====================
A/DT
prediction/NN
algorithm/NN
based/VBN
on/IN
SVM/NN
with/IN
common/JJ
and/CC
rare/JJ
variants/NNS
was/VBD
proposed/VBN
in/IN
order/NN
to/TO
improve/VB
predictive/JJ
performance/NN
[/(
55/CD
]/)
./.
====================
Second/RB
,/,
integrating/VBG
biological/JJ
knowledge/NN
into/IN
a/DT
risk/NN
prediction/NN
model/NN
will/MD
provide/VB
more/RBR
accurate/JJ
predictions/NNS
and/CC
biologically/RB
meaningful/JJ
interpretation/NN
./.
====================
Eleftherohorinou/NN
et/FW
al/JJ
./.
====================
[/(
56/CD
]/)
have/VBP
shown/VBN
success/NN
of/IN
a/DT
pathway-based/JJ
prediction/NN
test/NN
of/IN
GWAS/NN
data/NNS
./.
====================
Recently/RB
,/,
a/DT
pathway-based/JJ
approach/NN
was/VBD
proposed/VBN
to/TO
incorporate/VB
principal/JJ
components/NNS
of/IN
pathway/NN
effects/NNS
and/CC
pathway-covariate/NN
interactions/NNS
into/IN
logistic/JJ
regression/NN
[/(
57/CD
]/)
./.
====================
Furthermore/RB
,/,
a/DT
risk/NN
prediction/NN
model/NN
can/MD
be/VB
used/VBN
to/TO
investigate/VB
multiple/JJ
types/NNS
of/IN
omics/NNS
data/NNS
,/,
such/JJ
as/IN
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
datasets/NNS
./.
====================
The/DT
recent/JJ
developments/NNS
of/IN
single-molecule/JJ
sequencing/NN
technologies/NNS
(/(
i.e./FW
,/,
third-generation/NN
sequencing/NN
)/)
has/VBZ
facilitated/VBN
integrated/VBN
analysis/NN
of/IN
multi-omics/NNS
data/NNS
./.
====================
There/EX
is/VBZ
no/DT
doubt/JJ
that/DT
multi-omics/NNS
data/NNS
will/MD
lead/VB
to/TO
improvement/VB
of/IN
risk/NN
prediction/NN
models/NNS
./.
====================
Outline/NN
of/IN
the/DT
risk/NN
prediction/NN
model/NN
construction/NN
and/CC
validation/NN
./.
====================
T2D/DT
,/,
type/NN
2/CD
diabetes/VBZ
;/:
CV/NNP
,/,
cross-validation/JJ
;/:
ALL/NN
,/,
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
only/RB
reported/VBN
in/IN
the/DT
genome-wide/JJ
association/NN
study/RB
(/(
GWAS/NNP
)/)
catalog/NN
;/:
KARE/NNP
,/,
Korean/JJ
Association/NN
Resource/NNP
;/:
ASIAN/RB
,/,
SNPs/NNS
only/RB
reported/VBN
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
;/:
ALL/NN
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
and/CC
KARE/NN
cohort/RB
;/:
ASIAN/RB
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
and/CC
the/DT
KARE/NN
cohort/RB
;/:
SLR/NNP
,/,
stepwise/RB
logistic/JJ
regression/NN
;/:
LASSO/NNP
,/,
least/JJS
absolute/RB
shrinkage/RB
and/CC
selection/NN
operator/NN
;/:
EN/NNP
,/,
Elastic-Net/NNP
./.
====================
Venn/RB
diagrams/NNS
summarizing/VBG
the/DT
number/NN
of/IN
variables/NNS
shared/VBN
among/IN
5-fold/JJ
CV/NN
by/IN
variables/NNS
selection/NN
methods/NNS
./.
====================
CV/RB
,/,
cross-validation/JJ
;/:
ALL/NN
,/,
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
only/RB
reported/VBN
in/IN
the/DT
genome-wide/JJ
association/NN
study/RB
(/(
GWAS/NNP
)/)
catalog/NN
;/:
ASIAN/RB
,/,
SNPs/NNS
only/RB
reported/VBN
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
;/:
KARE/NNP
,/,
Korean/JJ
Association/NN
Resource/NNP
;/:
ALL/NN
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
and/CC
KARE/NN
cohort/RB
;/:
ASIAN/RB
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
and/CC
the/DT
KARE/NN
cohort/RB
;/:
SLR/NN
,/,
stepwise/RB
logistic/JJ
regression/NN
;/:
LASSO/NNP
,/,
least/JJS
absolute/RB
shrinkage/RB
and/CC
selection/NN
operator/NN
;/:
EN/NNP
,/,
Elastic-Net/NNP
./.
====================
Internal/JJ
validation/NN
shows/VBZ
the/DT
AUC/NN
values/NNS
for/IN
each/DT
combination/NN
of/IN
variable/JJ
selection/NN
and/CC
prediction/NN
methods/NNS
./.
====================
Each/DT
bar/JJ
represents/VBZ
one/CD
of/IN
five/CD
SNP/NN
data/NNS
sets/NNS
./.
====================
AUC/RB
,/,
area/NN
under/IN
the/DT
receiver/RB
operating/VBG
characteristic/JJ
curve/JJ
;/:
SNP/NN
,/,
single-nucleotide/JJ
polymorphism/NN
;/:
ALL/NN
,/,
SNPs/NNS
only/RB
reported/VBN
in/IN
the/DT
genome-wide/JJ
association/NN
study/RB
(/(
GWAS/NNP
)/)
catalog/NN
;/:
ASIAN/RB
,/,
SNPs/NNS
only/RB
reported/VBN
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
;/:
KARE/NNP
,/,
Korean/JJ
Association/NN
Resource/NNP
;/:
ALL/NN
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
and/CC
KARE/NN
cohort/RB
;/:
ASIAN/RB
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
and/CC
the/DT
KARE/NN
cohort/RB
;/:
SLR/NNP
,/,
stepwise/RB
logistic/JJ
regression/NN
;/:
LASSO/NNP
,/,
least/JJS
absolute/RB
shrinkage/RB
and/CC
selection/NN
operator/NN
;/:
EN/NNP
,/,
Elastic-Net/NNP
./.
====================
External/JJ
validation/NN
shows/VBZ
the/DT
AUC/NN
values/NNS
for/IN
each/DT
combination/NN
of/IN
variable/JJ
selection/NN
and/CC
prediction/NN
methods/NNS
./.
====================
Each/DT
bar/JJ
represents/VBZ
one/CD
of/IN
five/CD
SNP/NN
data/NNS
sets/NNS
./.
====================
AUC/RB
,/,
area/NN
under/IN
the/DT
receiver/RB
operating/VBG
characteristic/JJ
curve/JJ
;/:
SNP/NN
,/,
single-nucleotide/JJ
polymorphism/NN
;/:
ALL/NN
,/,
SNPs/NNS
only/RB
reported/VBN
in/IN
the/DT
genome-wide/JJ
association/NN
study/RB
(/(
GWAS/NNP
)/)
catalog/NN
;/:
ASIAN/RB
,/,
SNPs/NNS
only/RB
reported/VBN
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
;/:
KARE/NNP
,/,
Korean/JJ
Association/NN
Resource/NNP
;/:
ALL/NN
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
and/CC
KARE/NN
cohort/RB
;/:
ASIAN/RB
+/CC
KARE/NN
,/,
combined/JJ
SNPs/NNS
in/IN
the/DT
GWAS/JJ
catalog/NN
with/IN
an/DT
Asian/JJ
population/NN
and/CC
the/DT
KARE/NN
cohort/RB
;/:
SLR/NNP
,/,
stepwise/RB
logistic/JJ
regression/NN
;/:
LASSO/NNP
,/,
least/JJS
absolute/RB
shrinkage/RB
and/CC
selection/NN
operator/NN
;/:
EN/NNP
,/,
Elastic-Net/NNP
./.
====================
Demographic/JJ
variables/NNS
for/IN
KARE/NN
,/,
Health2/NN
,/,
and/CC
HEXA/NN
cohorts/NNS
====================
List/NN
of/IN
the/DT
SNP/NN
sets/NNS
====================
Number/NN
of/IN
overlapping/VBG
SNPs/NNS
selected/VBN
by/IN
5-fold/JJ
CV/NN
for/IN
each/DT
variable/JJ
selection/NN
method/NN
====================
Summary/JJ
of/IN
prediction/NN
performance/NN
in/IN
KARE/NN
testing/NN
dataset/NN
and/CC
an/DT
external/JJ
replication/NN
dataset/NN
====================
Development/NN
of/IN
SLR-SLR/NN
prediction/NN
model/NN
with/IN
one/CD
set/NN
from/IN
ALL/NN
+/JJ
KARE/NN
for/IN
predicting/VBG
T2D/NN
====================
